S-1: NeOnc Technologies Holdings Files S-1 for $50 Million Equity Line, Reveals Mounting Losses and Going Concern Warning

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company focused on brain cancers, has filed an S-1 registration statement to facilitate the resale of shares tied to a potential $50 million equity line of credit, while disclosing significant financial losses and a 'going concern' warning from its auditors.

Summary

• NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in treatments for intracranial malignancies (brain cancers) and developing novel drug delivery methods.
• The company's lead product, NEO100, a purified form of perillyl alcohol (POH), is in Phase IIa clinical trials for recurrent malignant glioma (Grade IV, IDH1 mutant and Grade III Astrocytoma, IDH1 mutant) and malignant skull-based meningioma.
• NEO100 has received Orphan Drug Designation and Fast Track status from the FDA for malignant glioma, and preclinical studies suggest its potential as a drug delivery vehicle for other therapeutics, including for Parkinson's disease.
• The second lead product, NEO212, a conjugated molecule of temozolomide and perillyl alcohol, has completed preclinical testing and received IND approval from the FDA, with a Phase I/II trial for oral administration in primary and secondary brain tumors initiated in Q4 2023.
• NEO212 also holds Orphan Drug Designation for glioma, brain metastases from breast cancer, and nasopharyngeal carcinoma.
• The company reported a net loss of $38,001,987 for the three months ended March 31, 2025, compared to $2,938,976 for the same period in 2024.
• For the years ended December 31, 2024 and 2023, net losses were $11,898,464 and $14,921,065, respectively.
• As of March 31, 2025, the accumulated deficit reached $88,610,432, up from $50,608,445 at December 31, 2024.
• The company had cash and cash equivalents of $5,439,210 as of March 31, 2025.
• The S-1 filing is primarily for the resale of up to 10,016,000 shares of common stock by Mast Hill Fund, L.P., related to an Equity Purchase Agreement (ELOC Financing) that could provide up to $50 million in gross proceeds to the company.
• The company's common stock was listed on The Nasdaq Global Market under the symbol NTHI on March 25, 2025.
• The auditor's report includes an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern due to significant losses and the need for additional funding.
• The company has no commercial products and has not generated significant revenue from product sales to date, with only $39,990 in revenue for Q1 2025 from a humanitarian program.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including substantial and increasing net losses, a large accumulated deficit, and an explicit 'going concern' warning from its auditors. While it has promising drug candidates in clinical trials and has recently listed on Nasdaq, the immediate financial outlook is highly precarious, and it relies heavily on future capital raises, which will likely cause further dilution. Outstanding litigation settlements also pose a financial burden.

Positives

• NEO100 has completed Phase I clinical trials and is currently in Phase IIa trials for recurrent malignant glioma and malignant skull-based meningioma, showing good tolerability and preliminary signs of therapeutic activity in some patients.
• In Phase I trials for recurrent glioblastoma, 55% of patients survived over one year, 33% over two years, and 25% over three years, which is noteworthy compared to the average life expectancy of about six months for this patient group.
• NEO100 received Orphan Drug Designation and Fast Track status from the FDA for treating malignant glioma, which may offer incentives and potential market exclusivity.
• The inclusion of Grade III IDH1,2 mutant astrocytomas in the NEO100 Phase IIa trial is expected to significantly expedite patient accrual and advance the data readout for Phase II studies to the end of 2024, a full year ahead of the original 2025 timeline.
• NEO212 has completed preclinical testing and received Investigational New Drug (IND) approval from the FDA in May 2023, allowing it to proceed to clinical testing in cancer patients.
• A Phase I/II trial for oral NEO212 in patients with primary and secondary brain tumors began in the fourth quarter of 2023.
• NEO212 has received Orphan Drug Designation for three different indications: glioma, brain metastases from breast cancer, and nasopharyngeal carcinoma.
• The company has developed novel drug delivery methods (intranasal, conjugated, intra-arterial) that aim to overcome the blood-brain barrier, potentially improving drug delivery to brain tumors and other CNS diseases.
• The company successfully completed a direct listing on the Nasdaq Global Market under the symbol NTHI on March 25, 2025.
• The company secured $11,644,005 in gross proceeds from private placements of common stock in March 2025.
• An Equity Purchase Agreement with Mast Hill Fund, L.P. provides the potential for up to $50 million in gross proceeds from future sales of common stock, offering a flexible funding source.

Negatives

• The company has incurred significant and increasing net losses, with a net loss of $38,001,987 for the three months ended March 31, 2025, and $11,898,464 for the year ended December 31, 2024.
• The accumulated deficit reached $88,610,432 as of March 31, 2025, indicating substantial historical losses.
• The company's independent registered public accounting firm included an explanatory paragraph in its report, raising substantial doubt about the company's ability to continue as a going concern.
• The company has not generated any revenue from product sales and does not anticipate generating significant revenues for the foreseeable future, relying heavily on external financing.
• The company is currently in default on a $600,000 litigation settlement payment to Fox Infused, with interest accruing since May 15, 2024.
• There is a dispute with Orient EuroPharma Co., Ltd. (OEP) regarding a $4.0 million settlement payment, as the company believes its direct listing is not an initial public offering, which OEP disputes.
• The sale of common stock to Mast Hill under the Equity Purchase Agreement may cause significant dilution to existing stockholders, and Mast Hill may sell shares immediately, potentially causing the stock price to decrease.
• The company has identified material weaknesses in its internal control over financial reporting, which could impair its ability to accurately and timely meet public company reporting requirements.

Risks

• Investing in the company's common stock involves a high degree of risk due to its early stage of development, lack of approved products, and significant operating losses.
• The sale or issuance of common stock to Mast Hill may cause substantial dilution to existing shareholders, and the sale of these shares by Mast Hill could cause the company's stock price to fall.
• The company requires substantial additional funding to sustain operations and pursue its growth strategy, and there is no assurance that future financing will be available on acceptable terms or at all.
• Failure to raise additional capital could force the company to delay, reduce, or eliminate research and development programs or future commercialization efforts.
• The company's management will have broad discretion over the use of net proceeds from stock sales, and these proceeds may not be invested successfully.
• The actual number of shares sold under the Equity Purchase Agreement and the resulting gross proceeds are unpredictable, as they fluctuate based on market prices.
• The commitment to issue shares could encourage short sales by third parties, potentially contributing to a decline in the stock price.
• The success of product candidates is highly uncertain and depends on successful completion of preclinical studies and clinical trials, regulatory approvals, and market acceptance.
• The company relies on third-party contract manufacturers and, in some cases, single-source suppliers, posing risks to manufacturing and supply.
• The company's intellectual property protection is uncertain, and issued patents may be challenged, potentially limiting competitive advantages.
• Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, private litigation, and adverse publicity.
• Significant uncertainty exists regarding coverage and reimbursement status for any approved products, which could limit marketability and revenues.
• Healthcare reform measures and cost-containment efforts by governments and third-party payors could adversely affect the company's revenues and profitability.
• The company is involved in legal proceedings, including outstanding litigation settlement payments that could result in direct and indirect costs and operational disruptions.

Future Outlook

NeOnc Technologies expects to continue incurring significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through preclinical and clinical development and seeks regulatory approval. The company does not anticipate generating significant revenues from product sales unless and until regulatory approval is obtained. It will require substantial additional funding, which it expects to finance through a combination of public or private equity offerings, debt financings, or potential collaboration agreements. The company projects that the data readout for its Phase II studies with respect to NEO100 could be delivered by the end of 2024, advancing its original timeline by a full year from 2025. It is also planning a Phase I clinical trial for intranasal NEO100 mixed with levodopa for Parkinson's disease and designing a Phase I/IIa trial for oral NEO212 specifically for newly-diagnosed glioblastoma.

Management Comments

• "We believe this targeted enrollment of both Grade III and IV IDH1,2 mutants may significantly expedite our trial process and we project that the readout for our Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025."

Industry Context

NeOnc Technologies operates within the highly competitive and rapidly evolving global central nervous system (CNS) treatment market and brain tumor drug market. The global CNS treatment market is projected to grow at a 9.4% CAGR to reach $166.5 billion by 2028, while the global brain tumor drug market is expected to grow at a 9.0% CAGR to $4.4 billion by 2029. The glioblastoma (GBM) drug market, a key focus for NeOnc, is anticipated to grow at a 12.7% CAGR to $2.3 billion by 2029, driven by an aging population and increasing incidence. Competition in these markets includes large pharmaceutical companies such as Bristol Myers Squibb (Opdivo), Merck & Co., Inc. (Temozolomide), Roche (Avastin), Novocure (Optune device), AstraZeneca, Eli Lilly and Company, Pfizer, and Celldex Therapeutics, as well as other treatment modalities like surgery and radiation therapy. NeOnc aims to differentiate itself through novel drug delivery methods and drug candidates that offer potentially better therapeutic results with fewer side effects, addressing current inefficiencies in drug delivery to the brain.

Comparison to Industry Standards

• NEO100's Phase I trial results for recurrent glioblastoma showed 55% of patients surviving over one year, 33% over two years, and 25% over three years, which is significantly longer than the typical average life expectancy of about six months for recurrent glioblastoma patients.
• Unlike previous oral perillyl alcohol (POH) formulations by other companies that failed due to rapid liver metabolism and significant gastrointestinal toxicity, NeOnc's intranasal NEO100 appeared well-tolerated with only minor side effects, suggesting a potentially superior delivery method and safety profile.
• NEO100 treatment did not lead to the typical harsh side effects (nausea, debilitating fatigue, anemia, infections, diarrhea, hair loss) often associated with conventional chemotherapies.
• Preclinical studies of NEO212 suggest its activity may be greater than the sum of its individual components (temozolomide and POH), indicating a potential synergistic effect not seen in conventional combination therapies.
• NEO212 preclinical data suggests it may overcome resistance mechanisms (e.g., MGMT positivity) that limit the effectiveness of standard chemotherapeutic agents like temozolomide.
• The company's intra-arterial delivery method for NEO100 is being investigated for its potential to temporarily open the blood-brain barrier, which may offer advantages over currently established clinical methods like mannitol for delivering drugs to the brain.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a dispute with Orient EuroPharma Co., Ltd. (OEP) regarding a $4,000,000 settlement payment from a terminated collaboration agreement. The company believes its Direct Listing is not an initial public offering, which OEP disputes, potentially leading to additional proceedings.
• The company is in default on a $600,000 settlement payment, plus an additional $25,000, to a vendor (Fox Infused) from a breach of contract complaint. Interest has been accruing on the unpaid balance since May 15, 2024.

Related Party Transactions

• **AFH Holdings and Advisory, LLC (AFH)**: Entered into an advisory agreement in December 2022. AFH earned a $500,000 fee in 2023 and 2024. In March 2025, the company incurred an $11,328,565 fee upon Nasdaq listing, with $2,500,000 paid upfront and the remaining $8,828,565 payable in 12 equal monthly installments. AFH also acts as an exclusive advisor for financing and M&A for two years post-listing. Amir Heshmatpour, a director and executive, is the sole member and managing director of AFH.
• **University of Southern California (USC)**: The company has an exclusive license agreement for patents. It issued 117,236 shares initially and 560,000 additional shares in October 2023. The company pays an annual patent maintenance fee of $20,000 and owes 2-4% earned royalties on net sales (none to date). As of March 31, 2025, the company owed USC approximately $118,011 for laboratory and patent maintenance services. In 2024, $1,377,096 owed to USC was converted into 114,758 common shares. A $230,000 payment for prior unpaid sublicense royalties is due by September 1, 2025, or within five days of a public offering. Dr. Thomas C. Chen, CEO and Chairman, is a faculty member at USC.
• **HCWG LLC**: This entity is owned by certain shareholders, directors, and officers, including Amir Heshmatpour, Dr. Thomas Chen, and Keithly Garnett. The company had a non-interest bearing Bridge Loan with HCWG LLC, with $11,748,464 outstanding principal and interest converted to 979,039 common shares in June 2024, terminating the loan. The company also has a Line of Credit Agreement with HCWG for up to $10.0 million, bearing 10.0% interest, and issued five-year warrants to HCWG for 312,500 shares at $12.00 per share. In March 2025, 162,500 warrants were exercised cashless. A $50,000 convertible note (Brownstone Note) was assigned to HCWG LLC in January 2024, amended to $62,500 principal, and converted to 5,208 common shares in July 2024.
• **Executive Chairman (Amir Heshmatpour)**: Advanced the company approximately $300,000 in February 2025, which was repaid in March 2025 for a total of $600,000 (including a 50% original issue discount).
• **Management Team (Shareholders)**: The company incurred $444,766 in accrued compensation for the management team as of March 31, 2025. In June 2024, $412,500 of outstanding accrued compensation was converted into 34,375 shares of common stock.
• **Orient EuroPharma Co., Ltd. (OEP)**: A collaboration agreement with OEP, partially owned by Alan Chiang (a former director), was terminated, resulting in a $4,000,000 settlement payment obligation.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from the Equity Purchase Agreement with Mast Hill and potential future capital raises. The company's substantial losses and 'going concern' warning pose a high risk to investment value. Sales by Mast Hill could depress the stock price. Existing shareholders' voting power may be diluted by future equity issuances.
• **Employees**: The company's financial instability and need for additional funding could impact job security and future compensation. Stock-based compensation (RSUs) are a significant part of executive compensation, with vesting contingent on company performance and listing.
• **Customers/Patients**: The development of novel treatments for aggressive brain cancers and Parkinson's disease offers potential future benefits for patients with limited treatment options, but the success and approval of these products are uncertain.
• **Suppliers/Creditors**: The company's default on a litigation settlement payment and reliance on debt financing (Line of Credit) indicate potential risks for suppliers and creditors regarding timely payments and repayment of obligations.
• **Regulatory Bodies (FDA)**: The company's compliance with FDA regulations and successful navigation of the drug approval process are critical for its business model and future revenue generation.

Next Steps

• Continue Phase IIa clinical trials for NEO100 in recurrent malignant glioma and malignant skull-based meningioma.
• Initiate a Phase I clinical trial for intranasal NEO100 mixed with levodopa for Parkinson's disease.
• Continue Phase I/II trial for oral NEO212 in patients with primary and secondary brain tumors.
• Design and potentially initiate a Phase I/IIa trial of oral NEO212 for newly-diagnosed glioblastoma.
• Conduct further preclinical development for intranasal NEO212 for uncontrolled brain metastases and intra-arterial delivery of NEO100 to open the blood-brain barrier.
• Seek regulatory approval from the FDA and other agencies for product candidates.
• Develop commercialization capabilities or establish third-party commercialization partnerships for approved products.
• Raise substantial additional funding through equity offerings, debt financings, or collaboration agreements to support ongoing operations and growth strategy.
• Address and resolve outstanding litigation settlement payments to OEP and Fox Infused.
• Implement and test remediation efforts to address identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Brain Cancer, Glioblastoma, Meningioma, Astrocytoma, Drug Delivery, Intranasal, Perillyl Alcohol, NEO100, NEO212, Clinical Trials, Phase IIa, Orphan Drug, FDA, NASDAQ, S-1 Filing, Equity Line of Credit, Dilution, Oncology, Neurology, Parkinson's Disease, Going Concern